Shattuck Labs, Inc. (NASDAQ:STTK) Receives $4.00 Average PT from Brokerages

Shattuck Labs, Inc. (NASDAQ:STTK) has been assigned a consensus recommendation of “Moderate Buy” from the seven research firms that are covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a hold recommendation, two have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $4.00.

STTK has been the subject of several research reports. Leerink Partners reduced their price target on shares of Shattuck Labs from $4.00 to $2.00 and set an “outperform” rating for the company in a research report on Thursday, August 14th. Wall Street Zen raised shares of Shattuck Labs to a “hold” rating in a research report on Friday, September 5th. Wedbush assumed coverage on shares of Shattuck Labs in a report on Monday. They set an “outperform” rating and a $4.00 price objective on the stock. Finally, Needham & Company LLC reissued a “hold” rating on shares of Shattuck Labs in a report on Thursday, August 14th.

Shattuck Labs Stock Down 12.9%

Shares of Shattuck Labs stock opened at $1.75 on Monday. The company has a market capitalization of $83.83 million, a price-to-earnings ratio of -1.45 and a beta of 1.64. Shattuck Labs has a 12-month low of $0.69 and a 12-month high of $3.95. The firm’s 50-day moving average price is $0.96 and its two-hundred day moving average price is $1.01.

Shattuck Labs (NASDAQ:STTK) last issued its quarterly earnings data on Thursday, August 14th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.01. On average, sell-side analysts expect that Shattuck Labs will post -1.48 earnings per share for the current year.

Insider Activity at Shattuck Labs

In other Shattuck Labs news, Director Mona Ashiya purchased 6,306,127 shares of the company’s stock in a transaction that occurred on Monday, August 25th. The stock was bought at an average price of $0.87 per share, with a total value of $5,486,330.49. Following the completion of the purchase, the director directly owned 5,255,106 shares of the company’s stock, valued at $4,571,942.22. The trade was a -600.00% increase in their position. The purchase was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Orbimed Advisors Llc acquired 6,306,127 shares of the stock in a transaction on Monday, August 25th. The shares were purchased at an average cost of $0.87 per share, with a total value of $5,486,330.49. Following the transaction, the director directly owned 5,255,106 shares of the company’s stock, valued at approximately $4,571,942.22. This trade represents a -600.00% increase in their position. The disclosure for this purchase can be found here. 12.00% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Shattuck Labs

A number of hedge funds have recently bought and sold shares of the business. Prosight Management LP increased its position in shares of Shattuck Labs by 15.1% during the 4th quarter. Prosight Management LP now owns 6,638,935 shares of the company’s stock valued at $8,033,000 after purchasing an additional 873,409 shares during the last quarter. Jane Street Group LLC increased its position in shares of Shattuck Labs by 2,510.8% during the 2nd quarter. Jane Street Group LLC now owns 289,671 shares of the company’s stock valued at $229,000 after purchasing an additional 278,576 shares during the last quarter. Y Intercept Hong Kong Ltd purchased a new stake in shares of Shattuck Labs during the 2nd quarter valued at about $98,000. Bank of America Corp DE increased its holdings in Shattuck Labs by 135.0% in the 4th quarter. Bank of America Corp DE now owns 187,089 shares of the company’s stock worth $226,000 after acquiring an additional 107,491 shares in the last quarter. Finally, ADAR1 Capital Management LLC purchased a new stake in Shattuck Labs in the 1st quarter worth approximately $97,000. Hedge funds and other institutional investors own 58.74% of the company’s stock.

Shattuck Labs Company Profile

Shattuck Labs, Inc, a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.